Once-a-day highly active antiretroviral therapy: A systematic review

Clinical Infectious Diseases

Volumn 36, Issue 9, 2003, Pages 1186-1190

  Ena, Javier ^a,b   Pasquau, Francisco ^a  

^a Marina Baixa Hospital   (Spain)

^b HOSPITAL MARINA BAIXA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE;

CLINICAL TRIAL; CONFERENCE PAPER; DATA BASE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL LITERATURE; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HIV; HIV INFECTIONS; HUMANS; LYMPHOCYTES; MALE; RANDOMIZED CONTROLLED TRIALS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037542551     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374602     Document Type: Review

References (16)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
2. Carmona A, Knobel H, Guelar A, et al. Factors influencing survival in HIV infected patients treated with HAART [abstract TuOrB417]. In: Program and abstracts of the 13th International AIDS Conference (Durban, South Africa). Stockholm: International AIDS Society, 2000: 333.
3. Bass D, Smith MF. HIV patients prefer once-daily regimens [abstract MoPeB3290]. In: Program and abstracts of the 14th International AIDS Conference. (Barcelona, Spain). Stockholm: International AIDS Society, 2002:80.
4. Fleiss JL. The measurement of interrater agreement in statistical methods for rates and proportions. New York: Wiley, 1981; 212-36.
5. Hsieh SM, Hung CC, Lu PL, Chen MY, Chang SC. Preliminary experience of adverse drug reactions, tolerability, end efficacy of a once-daily regimen of antiretroviral combination therapy. J Acquir Immun Defic Syndr 2000; 24:287-8.
6. Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users. Antivir Ther 1998; 3(Suppl 4):55-6.
7. Staszewski S, Haberl A, Carlebach A, Rottmann C, Miller V, Gute P. A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users. HIV Med 2000; 1:162-3.
8. Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001; 6:249-53.
9. Mole L, Schmidgall D, Holodniy M. A pilot trial of indinavir, ritonavir, didanosine and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr 2001; 27:260-5.
10. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000; 182:599-602.
11. Skowron G, Kuritzkes DR, Thompson MA, et al. Once-daily quadruple-drug therapy with adefovir dipivoxil, lamivudine, didanosine, and efavirenz in treatment-naive human immunodeficency virus type-1-infected patients. J Infect Dis 2002; 186:1028-33.
12. Jordan W, Jefferson R, Yemofio F, et al. Nevirapine (NVP) + efavirenz (EFV) + didanosine (ddI): a very simple, safe and effective once-daily regimen [abstract TuPeB3207]. In: Program and abstracts of the 13th International AIDS Conference (Durban, South Africa). Stockholm: International AIDS Society, 2000:358.
13. Landman R, Schiemann R, Thiam S, et al. Evaluation at 6 months of a once-a-day HAART regimen in treatment-naive HIV-1-infected adults in Senegal (ANRS 12-04 study) [abstract 491]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001:190.
14. Maggiolo F, Arici C, Gregis G, et al. A controlled, randomized, prospective study on a once-a-day therapy for HIV infection [abstract H-163]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:260.
15. Saag M, Cahn P, Raffi F, et al. A randomized double-blind, multicenter comparison of emtricitabine QD to stavudine BID [abstract LB-1]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:8.
16. Bertz R, Foit C, Ye X, et al. Pharmacokinetics of once-daily vs. twice-daily Kaletra (lopinavir/ritonavir) in HIV+ subjects [abstract 126]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:95.